Fig. 3.

Expression of TLR9 is significantly higher in ER– cancers than in highly ER+ breast cancers. TLR9 staining intensities within the individual samples were microscopically scored and stratified according to ER (a), PgR (b) and Her2 expression status (c) or according to triple negativity (ER–, PgR–, Her2–; d) and a combination of positive ER, PgR and/or Her2 status of the tumor. The mean TLR9 staining intensity was significantly higher (* p < 0.05) in the ER– tumors than in highly ER+ (ER3+) tumors.